Development of alpha-noradrenergic and Dopaminergic receptor systems depends on maturation of their presynaptic nerve terminals in the rat brain.
To study the relationship between ontogeny of rat brain catecholamine nerve terminals and the receptor systems for the catecholamine transmitters, the developmental patterns of synaptosomal uptake mechanisms were compared with those of alpha-noradrenergic and dopaminergic receptor-mediated effects. Uptakes of [(3)H]dopamine or [(3)H]norepinephrine into dopaminergic and noradrenergic nerve terminals were low during the 1st week postpartum and increased rapidly during the 2nd week. A similar pattern was obtained for ontogeny of dopaminergic receptor binding sites, as evaluated by [(3)H]domperidone binding. Stimulation of incorporation of (33)P(i) into brain phospholipids (elicited by intracisternal injection of dopamine), which is mediated by dopaminergic receptors, was shown to be highly correlated with the maturation of both receptor binding sites and presynaptic nerve terminal uptake. A similar result was seen with norepinephrine, in that the synaptosomal uptake mechanism and norepinephrine-induced stimulation (33)P(i) incorporation into phospholipids, an alpha-noradrenergic effect, developed in a parallel fashion. To test the hypothesis that development of the receptor systems is linked to nerve terminal ontogeny, presynaptic nerve terminals were destroyed in neonates by intracisternal administration of 6-hydroxydopamine. The lesions prevented the maturational increase in the number of dopamine receptor binding sites and produced a defect in development of the dopamine- and norepinephrine-induced stimulation of (33)P(i) incorporation. The results suggest that ontogeny of both dopaminergic and alpha-noradrenergic receptor systems depend upon development of the presynaptic nerve terminals containing the transmitters.
D000818:Animals; D001562:Benzimidazoles / Q000378:metabolism; D001921:Brain / Q000254:growth & development*; D004294:Domperidone; D004298:Dopamine / Q000494:pharmacology; D006892:Hydroxydopamines / Q000494:pharmacology; D009411:Nerve Endings / Q000502:physiology*; D009638:Norepinephrine / Q000494:pharmacology; D010710:Phosphates / Q000378:metabolism; D010743:Phospholipids / Q000378:metabolism; D010880:Piperidines / Q000378:metabolism; D051381:Rats; D011941:Receptors, Adrenergic / Q000502:physiology*; D011954:Receptors, Dopamine / Q000502:physiology*; D013574:Synaptosomes / Q000187:drug effects / Q000378:metabolism
D001562:Benzimidazoles; D006892:Hydroxydopamines; D010710:Phosphates; D010743:Phospholipids; D010880:Piperidines; D011941:Receptors, Adrenergic; D011954:Receptors, Dopamine; D004294:Domperidone; D004298:Dopamine; D009638:Norepinephrine